Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency
2020-001420-34Phase 2Completed
- Sponsor
- Aarhus University
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of senicapoc in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS) and respiratory failure, sponsored by Aarhus University. Primary endpoint: PaO2/FiO2 ratio at 72 hours. Started Apr 2020; status: completed.
02
Drugs
senicapoc
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)respiratory failure
Beyond the preview
Go deeper on 2020-001420-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001420-34.